Novel approaches to the treatment of acute renal failure

Bibliography

• NISSENSON AR: Acute renal failure: definition and pathogenesis. Kidney Int. (1998) 53 (Suppl. 66):S7–S10.
   Google Scholar
• •Comprehensive review up to 1998.
   Google Scholar
• HOU SH, BUSHINSKY DA, WISH JB et al: Hospital-acquired renal insufficiency: A prospective study. Am. J. Med. (1983) 74:243–248.
   PubMed Web of Science ®Google Scholar
• BRIVET FG, KLEINKNECHT DJ, LOIRAT P, FRENCH STUDY GROUP ON ACUTE RENAL FAILURE: Acute renal failure in intensive care units - causes, outcomes and prognostic factors of hospital mortality: a prospective multicenter study. Grit. Care Med. (1996) 24:192–198.
   PubMed Web of Science ®Google Scholar
• BELLOMO R, RONCO C: The changing pattern of severe acute renal failure. Nephrology (1991) 2:602–610.
   Google Scholar
• BREZIS M, ROSEN S, SILVA P et al.: Transport activity modifies the ascending limb damage in isolated perfused kidney. Kidney Int. (1984) 25:65–72.
   PubMed Web of Science ®Google Scholar
• SHILLIDAY I, ALLISON ME: Diuretics in acute renal failure. Ren. Fail. (1994) 16:3–17.
   PubMed Web of Science ®Google Scholar
• KELLUM JA: Use of diuretics in the acute care setting. Kidney Int. (1998) 53 (Suppl. 66):567–570.
   Google Scholar
• JOHNSON JP, ROKAW MD: Experimental acute renal failure. In: Acute Renal Failure in Critically III. Bellomo R, Ronco C (Eds.), Springer-Verlag, Heidelberg, Germany (1995):28–57.
   Google Scholar
• BREZIS M, EPSTEIN FH: Pathophysiology of acute renal failure. In: Toxicology of the Kidney (Second Edition). Hook JB, Goldstein RS (Eds.), Raven Press, NY, USA (1993) :129–152.
   Google Scholar
• LUCKE B: Lower nephron nephrosis. Milit. Surg. (1946) 99:371–396.
   PubMedGoogle Scholar
• OLIVER J, MCDOWELL M, TRACY A: The pathogenesis of acute renal failure associated with traumatic and toxic injury. j Clin. Invest. (1951) 30:1307–1351.
   PubMed Web of Science ®Google Scholar
• BREZIS M, ROSEN S, SPOKES K et al.: Transport-dependent anoxic cell injury in the isolated rat perfused kidney. Am. J Path. (1984) 116:327–341.
   PubMed Web of Science ®Google Scholar
• AGMON Y, PELEG H, GREENFELD Z et al.: Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. j Clin. Invest. (1994) 94:1069–1075.
   PubMed Web of Science ®Google Scholar
• HEYMAN S, FUCHS S, BREZIS M: The role of medullary ischemia in acute renal failure. New Horizons (1995) 3(4)597–607.
   Google Scholar
• ••Excellent review of the physiology of regulation of renalmedullary blood oxygenation.
   Google Scholar
• KATSUBE N, WAKITANI K, FOK KF et al.: Differential structure-activating relationships of atrial peptides as natriuretics and renal vasodilators in the dog. Biochem. Biophys. Res. Commun. (1985) 128:325–330.
   PubMed Web of Science ®Google Scholar
• NAPIER MA, VANDEEN RL, ALBERS-SCHONBERG G et al.: Specific membrane receptors for atrial natriuretic peptides in renal and vascular tissues. Proc. Natl. Acad. Sci. USA (1984) 81:5946–5950.
   PubMed Web of Science ®Google Scholar
• DUNN BR, ICHIKAWA I, PFEFFER JM, TROY JL, BRENNER BM: Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in anesthetized rat. Circ. Res. (1986) 59:237–246.
   PubMed Web of Science ®Google Scholar
• SONNENBERG H, HONRATH U, CHONG CK, WILSON DR: Atrial natriuretic factor inhibits Nattransport in medullary collecting duct. Am. J. Physiol (1986) 250:F963–F966.
   PubMed Web of Science ®Google Scholar
• SHAFFERHANS K, HEIBEREDER E, GRIM D et al.: Norepi-nephrine induced acute renal failures; beneficial effects of atrial natriuretic factor. Nephron (1986) 44:240–244.
   PubMedGoogle Scholar
• NAKAMOTO M, SHAPIRO JI, SHANLEY PF, CHAN L, SCHRIER RW: In vitro and in vivo protective effect of atriopeptin III on ischemic acute renal failure. J Clin. Invest. (1987) 80:698–705.
   PubMed Web of Science ®Google Scholar
• CONGER JD, FALK SA, YUAN BH, SCHRIER RW: AtrialNatriuretic peptide and dopamine in a rat model of ischemic acute renal failure. Kidney Int. (1989) 35:1126–1132.
   PubMed Web of Science ®Google Scholar
• AKABANE S, IMANISHI M, MATSUSHIMA Y et al.: Renalactions of atrial natriuretic peptide on the post-ischemic kidney. Can. J. Physic]. Pharmacol. (1988) 66:601–607.
   PubMed Web of Science ®Google Scholar
• POLLOCK DM, OPGENORTH TJ: Beneficial effect of theANP analog, A68828 on recovery from ischemic acute renal failure. Ren. Fail. (1992) 14:141–146.
   PubMed Web of Science ®Google Scholar
• CAPASSO G, ANASTASIO P, GIORDANO D, ALBARANO L, DE SANTO NG: Beneficial effects of atrial natriuretic factor on cisplatin-induced acute renal failure. Am. J Nephrol. (1987) 7:228–234.
   PubMed Web of Science ®Google Scholar
• GIANELLO P, RAMBOUX A, POLLART D et al.: Prevention of acute cyclosporine nephrotoxicity by atrial natriuretic factor after ischemia in the rat. Transplanta-tion (1988) 47:512–514.
   Web of Science ®Google Scholar
• SCHAFFERHANS K, HEIDBREDER E, SPERBER S, DAMMRICH J, HEIDLAND A: Atrial natriuretic peptide in gentamicin-induced acute renal failure. Kidney Int. (1988) 34 (Suppl. 25):S101–5103.
   Google Scholar
• BENTLY MD, FIKSEN-OLSEN MJ, ROMERO JC: Effect ofatriopep tin Hon contrast medium-induced changes in renal blood flow. Kidney Int. (1989) 36:13–19.
   PubMed Web of Science ®Google Scholar
• RAHMAN SN, KIM GE, MATHEW AS et al.: Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int. (1994) 45(6):1731–1738.
   PubMed Web of Science ®Google Scholar
• ALLGREN RL, MARBURY TC, RAHMAN SN et al: Anaritide in ATN. (Auriculin anaritide ARF study group). N Engl. J. Med. (1997) 336(12):828–834.
   PubMed Web of Science ®Google Scholar
• ALLGREN RL: Update on clinical trials with atrial natriuretic peptide in acute tubular necrosis. Ren. (1998). 20(5):691–695.
   PubMed Web of Science ®Google Scholar
• ••Good review of the literature on atrial natriuretic peptide upto 1998.
   Google Scholar
• KUMIK BR, ALLGREN RL, GENTER FC et al.: Prospective study of atrial natriuretic peptide for the prevention of radiocontrast- induced nephropathy. Am. J Kidney Dis. (1998) 31 (0674–680.
   PubMed Web of Science ®Google Scholar
• VALSSON F, RICKSTEN SE, HEDNER T, LUNDIN S: Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery. Int. Care Med. (1996) 22(3):230–236.
   PubMed Web of Science ®Google Scholar
• SANDS JM, NEYLAN JF, OLSON RA et al.: Atrial natriuretic factor does not improve the outcome of cadaveric renal transplantation. J. Am. Soc. Nephrol. (1991) 2:212–218.
   PubMedGoogle Scholar
• GOTA R, HEIDBREDE E, LANDHER G et al.: Impairedresponse to intra-r en al administration of atrial natriuretic peptide in ischemic acute renal failure of a transplant patient. Miner. Electrolyte Metab. (1990) 16:34–37.
   PubMedGoogle Scholar
• SAXENHOFER H, RASELLI A, WEIDMANN P et al.: Urodilantin, a natriuretic factor from kidneys can modify renal and cardiovascular system in men. Am. J. Physiol. (1990) 259:F832–F838.
   PubMed Web of Science ®Google Scholar
• HUMNEL M, KUHN M, BUB A et al.: Urodilantin: a newpeptide with beneficial effects in post-operative therapy of cardiac transplant recipients. Clin. Invest. (1992) 70:647–682.
   Google Scholar
• WIEBE K, MEYER M, WAHLERS T et al: Acute renal failurefollowing cardiac surgery is reverted by administra-tion of urodilantin (INN: Ularitide). Eur. j Clin. Invest. (1996) 1:259–265.
   Google Scholar
• CEDIDI C, MEYER M, KUSE ER et al.: Urodilantin: a newapproach for treatment of therapy-resistant acute renal failure after liver transplantation. Eur. j Clin. Invest. (1994) 24(9):632–639.
   PubMedGoogle Scholar
• MEYER M, PFARR E, SCHIRMER G et al.: Therapeutic use of natriuretic peptide ularitide in acute renal failure. Ren. Fail. (1999) 21(0:85–100.
   PubMedGoogle Scholar
• MAXWELL W: Natriuretic peptides and acute renal failure. New Horizons (1995) 3 (4):624–633.
   PubMedGoogle Scholar
• OSWALD H, MUHLBAUEER B, VALLON V: Adenosine andtubuloglomerular feedback. Blood Puri! (1997) 15 (4-6):243–252.
   PubMed Web of Science ®Google Scholar
• •Good overview of the physiology of tubuloglomerular feedback.
   Google Scholar
• WEIHBRECHT H, LORENZ JN, BRIGGS JP, SCHNERMANN J: Synergistic effects of angiotensin and adenosine in the renal microvasculature. Am. J Physiol. (1994) 266:F227–F239.
   PubMed Web of Science ®Google Scholar
• AREND LJ, BAKRIES GL, BURNETT JCJ et al.: Role forintrarenal adenosine in the renal hemodynaimc response to contrast media. J Lab. Clin. Med. (1987) 110:406–411.
   PubMed Web of Science ®Google Scholar
• ERLEY CM, DUDA SH, SCHLEPKOW S et al.: Adenosineantagonist theophylline prevents the reduction of glomerular filtration rate after contrast media applica-tion. Kidney Int. (1994) 45:1425–1431.
   PubMed Web of Science ®Google Scholar
• KOLONKO A, WIECEK A, KOKOT F: The non-selectiveadenosine antagonist theophylline does prevent renal dysfunction induced by radio contrast agents. J. Nephrol. (1998) 11 (3) :151–156.
   PubMed Web of Science ®Google Scholar
• ERLEY CM, DUDA SH, REHFUSS D et al.: Prevention of radiocontrast media-induced nephropathy in patients with pre-existing renal insufficiency by hydration in combination with adenosine-antagonist theophylline. Nephrol. Dial. Transplantation (1999) 14 (5):1146–1149.
   PubMed Web of Science ®Google Scholar
• KELLUM JA: The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence. Crit. Care (1997) 1:53–59.
   PubMedGoogle Scholar
• SERI I, KONE BC, GULLANS SR et al.: locally formeddopamine inhibits Na-K ATPase activity in rat renal cortical tubule cells. Am. J. Physiol. (1988) 255:F666–F673.
   PubMed Web of Science ®Google Scholar
• HEYMAN SN, KAMINSKI N, BREZIS M: Dopamine increases renal medullary blood flow without improving regional hypoxia. Exp. Nephrol. (1995) 3 (6):331–337.
   PubMedGoogle Scholar
• OLSEN NV, HAMSEN JM, LADEFOGED SD et al: Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man. Clin. Sci. (1990) 78:503–507.
   PubMed Web of Science ®Google Scholar
• DENTON MD, CHERTOW GM, BRADY HR: 'Renal-dose' dopamine for the treatment of acute renal failure: Scientific rationale, experimental studies and clinical trials. Kidney Int. (1996) 49:4–14.
   Web of Science ®Google Scholar
• MILLER ED: Renal effects of dopamine. Anesthesiology (1984) 61:487–488.
   PubMed Web of Science ®Google Scholar
• AURORA RN, MILITE F, CARLON G: Preventing renal failure in critically ill patients. Grit. Care Med. (1999) 27 (9):2044–2045.
   PubMed Web of Science ®Google Scholar
• LOKHANDWALA MF: Effects of dopamine receptor agonists on cardiovascular and renal function. In: Update in Intensive Care and Emergency Medicine. Vincent JL (Ed.), Springer-Verlag, Heidelberg, Germany (1990:74–90.
   Google Scholar
• ALLISON NL, DUBB JW, ZIEMNIAK JA, ALEXANDER F, STOTE RM: The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics. Clin. Pharmacol. Ther. (1987) 41:282–288.
   PubMed Web of Science ®Google Scholar
• HAHN RA, WARDELL JR, SARAU HM, RIDLEY PT: Charac-terization of the peripheral and central effects of SK and F 82526, a novel dopamine receptor agonist. Pharmacol. Exp. Ther. (1982) 223:305–313.
   PubMed Web of Science ®Google Scholar
• HARVEY JN, WORTH DP, BROWN J, LEE MR: The effect of oral fenoldopam (SK and F 825264), a peripheral dopamine receptor agonist, on blood pressure and renal function in normal man. Br. J. Clin. Pharmacol. (1985) 19:21–27.
   PubMed Web of Science ®Google Scholar
• ELLIOTT WJ, WEBER RR, NELSON KS et al.: Renal andhemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circula-tion (1990) 81:970–977.
   PubMed Web of Science ®Google Scholar
• CAREY RA, WEIDLEY EF, ACKERMAN DM: effect of SKand F 82526 on renal vascular resistance following acute myocardial infarction in the dog. Fed. Proc. (1982) 41:1092. Abstract.
   Google Scholar
• HEDRICH D, STOTE RM: Fenoldopam reversescyclosporine-A induced renal vasoconstriction in kidney transplant recipients. Am. J Kidney Dis. (1992) 19:567–572.
   PubMed Web of Science ®Google Scholar
• NICHOLS AJ, KOSTER PF, BROOKS DP, RUFFOLO RR, JR.: Effect of fenoldopam on the acute and subacute nephrotoxic renal failure produced by amphotericin Bin the dog./ Pharmacol. Exp. Ther. (1991) 260:269–274.
   Google Scholar
• CAREY RM, STOTE RM, DUBB JW, TOWNSENT LH, ROSE CE, JR., KAISER DL: Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. J. Clin. Invest. (19 8 4) 74:2198-2207.
   Google Scholar
• SHUSTERMSN NH, ELLIOT WJ, WHITE WB: Fenoldopambut not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am. J Med. (1993) 95:161–168.
   PubMed Web of Science ®Google Scholar
• SHUSTER HP, SUTER PM, HEMMER M, CLEMENS R, BODMAN KF, RAMOND J: Fenoldopam improves renal dysfunction secondary to ventilation with PEEP. Intensive Care Med. (1991) 28:348–355.
   Google Scholar
• MUNGER M, BENOTTI J, GREEN J, JARVIS RC: Assessmentof hemodynamic tolerance from a 24-hour intrave-nous infusion of fenoldopam mesylate in congestive heart failure. Am. J. Cardiol. (1990) 65:206–210.
   PubMed Web of Science ®Google Scholar
• HANDENGUE A, MOREAU R, BACQ Y, GAUDIN C, BRAILLON A, LEBREC D: Selective dopamine receptor-1 stimulation with fenoldopam in cirrhotic patients with ascites: A systemic, splanchnic and renal hemodynamic study. Hepatology (1991) 13:111–116.
   PubMed Web of Science ®Google Scholar
• MATHUR VS, SWAN SK, LAMBRECHT LJ et al.: The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normoten-sive subjects. Grit. Care Med. (1999) 27(9):1832–1837.
   PubMed Web of Science ®Google Scholar
• SCHRIER RW, ARNOLD PE, VAN PUTTEN VJ, BURKE TJ: Cellular calcium in ischemic acute renal failure. Kidney Int. (1987) 32:313–321.
   PubMed Web of Science ®Google Scholar
• LEE SM, HILLMAN BJ, CLARK RL, MICHAEL UF: The effectsof diltiazem and captopril on glycerol-induced acute renal failure in the rat: function, pathologic and micro angiographic studies. Invest. Radio. I. (1985) 20:961–970.
   PubMed Web of Science ®Google Scholar
• WATSON AJ, GIMENEZ LF, KLASSEN DK, STOUT RL, WHETTON A: Calcium-channel blockade in experi-mental; aminoglycoside nephrotoxicity. J. Clin. Pharmacol. (1987) 27:625–627.
   PubMed Web of Science ®Google Scholar
• PAPADIMITROU M, ALEXOPOULOUS E, VARGEMEZIS V,SAKELLARIOU G, KOSMIDOU I, METAXOS P: The effect of preventive administration of verapamil on ischemic renal failure in dogs. Kidney Int. (1983) 24:415. Abstract.
   Google Scholar
• EPSTEIN M: Calcium antagonists and the kidney: Futuretherapeutic perspectives. Am. J. Kidney Dis. (1993) 21(6, Suppl. 3):16–25.
   Google Scholar
• EPSTEIN M, DE MICHELLI AG, FORSTER H: Natriureticeffects of calcium antagonists in humans: A review of experimental evidence and clinical data. Cardiovasc. Drug Rev. (1991) 9:399–413.
   Google Scholar
• GASTONE L, ALESSANDRO R: Are there differences inthe renal effects of calcium antagonists? J Hypertens. (1992) 1 0 (Suppl. 0:345–348.
   Google Scholar
• BAKRIS GL, BURNETT JC: A role for calcium in r adio con-trast induced reductions in renal hemodynamics. Kidney Int. (1985) 27:465–468.
   PubMed Web of Science ®Google Scholar
• NEUMAYER HH, JUNGE W, KUFNER A, WENNING A: Prevention of radiocontrast-induced nephrotoxicity by the calcium-channel blocker nitrendipine: A prospective, randomized clinical trial. Nephrol. Dial. Transplant. (1989) 4:1030–1036.
   PubMed Web of Science ®Google Scholar
• RUSSO D, TESTA A, DELLA VL, SANSONE G: Randomizedprospective study on renal effects of two different contrast media in humans: Protective role of calcium-channel blocker. Nephron (1990) 55:254–257.
   PubMed Web of Science ®Google Scholar
• SEYSS C, FOOTE EF: Calcium-channel blockers for prophylaxis of radiocontrast associated nephrotox-icity. Ann. Pharmacother. (1995) 29(2):187–188.
   PubMed Web of Science ®Google Scholar
• •Good evidence-based discussion of the role of calcium-channel blockers in prevention of radio-contrast-induced nephrotoxicity.
   Google Scholar
• DUGGAN KA, MACDONALD GJ, CHARLESWORTH JA, PUSSELL BA: Verapamil prevents post-transplant olig-uric renal failure. Clin. Nephrol (1985) 24:289–291.
   PubMed Web of Science ®Google Scholar
• WAGNER K, ALBRECHTS S, NEUMAYER HH: Preventionof post-transplant acute tubular necrosis by calcium antagonist diltiazem: a prospective randomized study. Am. J. Nephrol (1987) 7:287–291.
   PubMed Web of Science ®Google Scholar
• NEUMAYER HH, WAGNER K: Prevention of delayed graft dysfunction in cadaver kidney transplantation by diltiazem: Outcome of two prospective, random-ized, clinical trials. J. Cardiovasc. Pharmacol. (1987) 10:S170–S177.
   PubMed Web of Science ®Google Scholar
• FRET U, HARMS A, SCHINDLER R: Kidney graft pretreat-ment by diltiazem reduces the rate of acute renal failure after transplantation. Proceedings of the Int. Symposium on Calcium Antagonists. Basel, Switzerland (1988). Abstract 35.
   Google Scholar
• DAVIDSON I, ROOTH P: Effects of calcium antagonistsin ameliorating cyclosporine A nephrotoxicity and post-transplant acute tubular necrosis. In: Calcium Antagonists and Kidney Epstein M (Ed.), Hanley and Belfus, Philadelphia PA, USA (1990):233–246.
   Google Scholar
• ALIVANIS P, GREKAS D, SIULIS A eta].: Effect of calcium-antagonist on renal graft function. Ren. Fail. (1993) 15 (1):81–83.
   Google Scholar
• LOUTZENHISER R, EPSTEIN M, HORTON C, SONKE P: Reversal of renal and smooth muscle actions of thromboxane mimetic U-44069 by diltiazem. Am. J Physiol. (1986) 251:F581–F587.
   PubMed Web of Science ®Google Scholar
• DAWIDSON I, ROOTH P, FRY WR et al: Prevention ofacute cyclosporine-induced renal blood flow inhibi-tion and improved immunosuppression with verapamil. Transplantation (1989) 48:575–580.
   PubMed Web of Science ®Google Scholar
• BERG KJ, HOLDASS H, ENDRESEN L et al.: Effects ofisradipine on renal function in cyclosporine-treated renal transplanted patients. Nephrol Dial. Transplant. (1991) 6:725–730.
   PubMed Web of Science ®Google Scholar
• NEUMAYER HH, KUNZENDORF U, SCHREIBER M: Protec-tive effects of diltiazem and prostacycline analogue iloprost in human renal transplantation. Ren. (1992) 14(3):289–296.
   PubMed Web of Science ®Google Scholar
• VAN RIEMSDIJK IC, MULDER PG, DE FIJTER JW et al.:Addition of Isradipine (lomir) results in a better renal function after kidney transplantation: A double-blind, randomized, placebo-controlled, multi-center study. Transplantation (2000) 70:122–126.
   Google Scholar
• MADEDDU P, ROFFA C, GLORIOSO N et al.: Effect ofendothelin on regional hemodynamics and renal function in awake normotensive rats. J Cardiovasc. Pharmacol. (1989) 14:818–825.
   PubMed Web of Science ®Google Scholar
• BRAUN C, LANG C, HOCHER B, GRETZ N, VAN DER WOUDE FJ, ROHMEISS P: Influence of the renal endothelin system on the autoregulation of renal blood flow in spontaneously hypertensive rats. Kidney Blood Press. Res. (1997) 20:6–10.
   PubMed Web of Science ®Google Scholar
• KON V, YOSHIOKA T, FOGO A, ICHIKAVA I: Glomerularactions of endothelin in vivo. J. Clin. Invest. (1989) 83:1762–1767.
   PubMed Web of Science ®Google Scholar
• TOMITA K, UJJIE K, NAKANISHI T et al.: Plasma endothelin levels in acute renal failure. N Engl. J Med. (1989) 321 (16) :1127.
   PubMed Web of Science ®Google Scholar
• SHIBOUTA Y, SUZUKI N, SHINO A et al: Pathophysio-logical role of endothelin in acute renal failure. Life Sci. (1990) 46:1611–1618.
   PubMed Web of Science ®Google Scholar
• KING AJ, BRENNER BM, ANDERSON S: Endothelin: a potent renal and systemic vasoconstrictor peptide. Am. J. Physic)]. (1989) 256:F1051–1058.
   PubMed Web of Science ®Google Scholar
• MARGUILES KB, HILDEBRAND FLJ, HEUBLEIN DM, BURNETT JCJ: Radiocontrast increases plasma and urinary endothelin -1. J. Am. Soc. Nephrol. (1991) 2:1041–1045.
   PubMed Web of Science ®Google Scholar
• WATSCHINGER B, VYCHYTIL A, SCHULLER M, HARTTER E, TRAINDL 0: The pathophysiological role of endothelin in acute vascular rejection after renal transplantation. Transplantation (1991) 52:743–746.
   PubMed Web of Science ®Google Scholar
• KNOLL T, SCHAUB M, BIRCK R, BRAUN C, JUENEMANN KP, ROHMEISS P: The renoprotective potential of endothelin receptor antagonists. Exp. Opin. Invest. Drugs (2000) 9(5):1041–1052.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of the pathophysiological role of endothe-lins in acute renal failure.
   Google Scholar
• GELLAI M, JUGUS M, FLETCHER T, DE WOLF R, NAMBI P:Reversal of post-ischemic acute renal failure with a selective endothelin-A receptor antagonist in the rat. J Clin. Invest. (1994) 93:900–906.
   PubMed Web of Science ®Google Scholar
• CHAN L, CHITTINANDANA A, SHAPIRO JI, SHANLEY PF, SCHRIER RW: Effect of and endo thelin-recep tor antago-nist on ischemic acute renal failure. Am. J Physic)]. (1994) 226:F135–F138.
   Google Scholar
• LANESE DM, CONGER BD: Effects of endothelin-receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J. Clin. Invest. (1993) 91:2144–2149.
   PubMed Web of Science ®Google Scholar
• BROOKS DP, CONTINO LC: Prevention of cyclosporine A- induced renal vasoconstriction by endothelin receptor antagonist SB 20967 O. Eur. Pharmacol (1995) 294:571–576.
   PubMed Web of Science ®Google Scholar
• HEYMAN SN, CLARK BA, KAISER N et al: radiocontrast agents induce endothelin release in vivo and in vitro. J. Am. Soc. Nephrol (1992) 3:58–65.
   PubMed Web of Science ®Google Scholar
• POLLOCK DM, POLAKOWSKI JS: Beneficial effect of ETA receptor blockade in radiocontrast-induced nephro-p athy in the rat. J. Am. Soc. Nephrol. (1995) 6:667. Abstract.
   Google Scholar
• ROHMEISS P, BIRCK R, BRAUN C, KIRCHENGAST M, VAN DER WOUDE F: Targets for endothelin in the diseased kidney: clues for therapeutical intervention. Exp. Nephrol. (1999) 7:1–10.
   PubMedGoogle Scholar
• BALIGA R, UEDA N, WALKER PD, SHAH SV: Oxidant mechanisms in toxic acute renal failure. Am. J Kidney Dis. (1997) 29:465–477.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, LASS N, GABER AO, JONES JD, BURNETT JC, JR.: Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am. J Physiol. (1990) 258:F115–F120.
   Google Scholar
• DIMARI J, MEGYESI J, UDVARHELYI N, PRICE P, DAVIS R, SAFIRSTEIN R: N-acetylcysteine ameliorates ischemic renal failure. Am. J Physiol. (1997) 272:F292–F298.
   PubMed Web of Science ®Google Scholar
• BRADY HR, SINGER GG: Acute renal failure. Lancet (1995) 346:1533–1540.
   PubMed Web of Science ®Google Scholar
• TEPEL M, VAN DER GIET M, SCHWARZFELD C, LAUFER U, LIERMANN D, ZIDEK W: Prevention of Radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl. J Med. (2000) 343:180–184.
   PubMed Web of Science ®Google Scholar
• KELLY KJ, WILLIAMS WW, COLIN RB et al.: Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc. Natl. Acad. Sci. USA (1994) 91:812–816.
   PubMed Web of Science ®Google Scholar
• GOLIGORSKY MS, NOIRI E, KESSLER H, ROMANOV V: Therapeutic effect of arginine-glycine-aspartic acid peptides in acute renal injury. Gin. Exp. Pharmacol. Physiol. (1998) 25:276–279.
   PubMed Web of Science ®Google Scholar
• ITO S, CARRETERO OA, ABE K: Nitric oxide in the regula-tion of renal blood flow. New Horizons (1995) 3(0615–623.
   PubMedGoogle Scholar
• SCHRAMM L, HEIDBREDER E, LOPAU K et al.: Toxic acute renal failure in the rat: Effects of L-Arginine and N-methyl-L-Arginine on renal function. Nephrol. Dial. Transplant. (1994) 9 (Suppl. 4):88–93.
   Google Scholar
• KATTELER M, BORDER WA, NOBEL NA: Cytokines and L-arginine in renal injury and repair. Am. J. Physiol. (1994) 267:F197–F204.
   Web of Science ®Google Scholar
• NATH KA, BALLA J, CROATT AJ: Heme protein-mediated renal injury: A protective role for 21 -aminosteroids in vitro and in vivo. Kidney Int. (1995) 47:592–602.
   PubMed Web of Science ®Google Scholar
• BRIGGS JD, KENNEDY AC, YOUNG LN et al.: Renal function after acute tubular necrosis. BMJ (1967) 3:513–516.
   PubMed Web of Science ®Google Scholar
• LEWERS DT, MATHEW TH, MAHER JF et al.: Long-term follow-up of renal function and histology after acute tubular necrosis. Ann. Int. Med. (1970) 73:523–529.
   PubMed Web of Science ®Google Scholar
• TOBACK FG: Regeneration after acute tubular necrosis. Kidney Int. (1992) 41:226–246.
   PubMed Web of Science ®Google Scholar
• BONVENTURE JV: Mechanisms of ischemic acute renal failure. Kidney Int. (1993) 43:1160–1178.
   PubMed Web of Science ®Google Scholar
• HAMMERMAN MR, MILLER SB: The growth hormone Insulin-like growth factor axis in kidney revisited. Am. Physiol. (1993) 265:F1–F14.
   PubMed Web of Science ®Google Scholar
• HUMES HD, CIESLINSKI DA, COIMBRA TM, MESSANA JM, GLAVAO C: Epidermal growth factor enhances renal tubular cell regeneration and repair and accelerates the recovery of renal failure. J Clin. Invest. (1989) 84:1757–1761.
   PubMed Web of Science ®Google Scholar
• NORMAN J, TSAU K, BECAY A, FINE LG: Epidermal growth factor accelerates functional recovery from ischemic acute tubular necrosis in the rat: Role of epidermal growth factor receptor. Clin. Sci. (1990) 78:445–450.
   PubMed Web of Science ®Google Scholar
• MILLER SB, MARTIN DR, KISSANE J, HAMMERMAN MR: Insulin-like growth factor-1 accelerates recovery from ischemic acute tubular necrosis in the rat. Proc. Nati Acad. Sci. USA (1992) 89:11876–11880.
   PubMed Web of Science ®Google Scholar
• MORIN NL, LAURENT G, NONCLERCQ D et al.: Epidermal growth factor accelerates renal repair in a model of gentamicin nephrotoxicity in rats. Am. J Physiol. (1992) 263:F806–F811.
   PubMed Web of Science ®Google Scholar
• MILLER SB, MARTIN DR, KISSANE J, HAMMERMAN MR: Rat model for the clinical use of insulin-like growth factor-1 in acute renal failure. Am. J Physiol. (1994) 266:F949–F956.
   PubMed Web of Science ®Google Scholar
• ALLEN BT, ANDERSON CB, RUBIN BG, FLYE MW, BAUMANN DS, SICARD GA: Preservation of renal function in juxtarenal and suprarenal abdominal aortic aneurysm repair. .J. Vasc. Surg. (1993) 17:948–959.
   PubMed Web of Science ®Google Scholar
• FRANKLIN C, MOULTON M, SICARD G, HAMMERMAN M, MILLER S: Insulin-like growth factor-1 preserves renal function post-operatively. Am. J. Physiol. (1997) 272:F257–F259.
   PubMed Web of Science ®Google Scholar
• KOPPLE JD, HIRSCHBERG R, GULER HP, PIKE M, CHIRO STUDY GROUP: lack of effect of recombinant human insulin-like growth factor-1 in patients with acute renal failure. J. Am. Soc. Nephrol. (1996) 7:1375. Abstract.
   Google Scholar